Photocure ASA Reports Impressive Growth in Q2 2025 Results

Strong Performance in the Second Quarter of 2025

Photocure ASA (OSE: PHO) has announced exceptional financial results for the second quarter of 2025. The company's revenues for Hexvix/Cysview reached NOK 135.6 million, marking a substantial increase from NOK 122.4 million in the same quarter the previous year. Additionally, the EBITDA stood at NOK 14.8 million, although slightly down from NOK 27.8 million in Q2 2024, which included a substantial milestone payment of NOK 21.6 million.

The company has set optimistic expectations for the remainder of the year, predicting product revenue growth of 7% to 11% with improvements in EBITDA year-over-year. Although specific EBITDA guidance is not being issued, Photocure anticipates continued operational leverage and significant growth in milestone payments throughout the year.

Key Insights from CEO Dan Schneider

CEO Dan Schneider expressed satisfaction with the results, highlighting that the company achieved all-time high revenues for Hexvix/Cysview and has maintained a streak of nine consecutive quarters of positive EBITDA. The company’s recent performance can be attributed to solid growth from its U.S. operations, where active accounts have increased by 24%.

Despite a decline in flexible cystoscopy kits, Photocure is optimistic about U.S. unit growth accelerating in the coming years. In Q2 alone, rigid kit sales surged by 21%, highlighting strong market demand.

Expansion of Blue Light Cystoscopy

In line with their strategic plans, Photocure progressed in expanding blue light cystoscopy usage. This included the installation of 12 new Saphira™ towers in the U.S., comprised of three new accounts and nine upgrades of existing facilities. By the end of the quarter, the company boasted 359 active accounts in the U.S., underscoring a strong growth trajectory compared to the previous year.

Across Europe, the company has successfully installed 36 Olympus Visera Elite III systems, enhancing blue light cystoscopy capabilities since their launch earlier this year. Schneider expects this new equipment to boost Hexvix sales in both the Nordic countries and mainland Europe significantly.

Future Partnerships and Innovations

Photocure is keen on exploring new partnerships that combine blue light cystoscopy with innovative products and technologies. A notable example is the partnership with Richard Wolf, which is progressing positively. Furthermore, they are also developing a flexible BLC interim solution ahead of launching a high-definition 4K system.

The company holds a license agreement with Asieris for Cevira, which could unlock potential milestone payments upon regulatory approval in China, further enhancing their financial outlook for 2025. They reaffirm their guidance for product revenue growth and EBITDA improvement this year, indicating confidence in their strategic direction.

Contact Information and About Photocure ASA

For further details, interested parties can contact CEO Dan Schneider or CFO Erik Dahl. Schneider emphasizes that Photocure ASA is dedicated to improving the lives of bladder cancer patients through transformative solutions. Their cutting-edge technology enables better detection, which significantly enhances patient outcomes.

Photocure ASA is based in Oslo, Norway, and is proud to be listed on the Oslo Stock Exchange under the ticker symbol PHO. To learn more about the company’s advancements and future developments, please visit their official website.

Frequently Asked Questions

1. What were the key financial results for Photocure ASA in Q2 2025?

In Q2 2025, Photocure ASA reported revenues of NOK 135.6 million and an EBITDA of NOK 14.8 million.

2. How does the company expect its revenue to grow?

Photocure anticipates product revenue growth between 7% and 11% in 2025, alongside improvements in EBITDA.

3. What initiatives did Photocure ASA undertake in Q2 2025?

The company installed 12 new Saphira™ towers in the U.S. and increased the number of active accounts by 24%.

4. What equipment has been installed in Europe to enhance services?

A total of 36 Olympus Visera Elite III blue light cystoscopy systems have been installed since their launch in Q1 2025.

5. How is Photocure ASA enhancing partnerships for future growth?

Photocure ASA is pursuing collaborations that integrate blue light cystoscopy with innovative technologies, including partnerships with companies like Richard Wolf.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.